ArticleCurrent drug targets2026
Robust Association of Breast Cancer Co-morbidity Using Subtype-specific Expressed Genes.
Article in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is a heterogeneous disease characterized by complex genetic and molecular alterations that drive its progression and metastasis to distant organs. It frequently cooccurs with comorbid conditions, which complicates diagnosis, treatment planning, and overall prognosis. Understanding the genetic overlap between breast cancer and comorbid diseases is therefore critical for improving precision medicine approaches and clinical outcomes.
methodsWe performed a comprehensive comorbidity assessment for breast cancer using gene-level associations and identified 194 diseases strongly associated with the disease. Gene Ontology and pathway-based analyses were conducted to explore functional overlaps. In addition, differential gene expression profiles were analyzed across major breast cancer subtypes, Luminal, HER2-enriched, and Basal-like, to investigate subtype-specific molecular contributions to comorbidity and metastasis.
resultsWe identified strong associations between breast cancer and several disease classes, including neoplastic, respiratory, digestive, cardiovascular, and musculoskeletal disorders. Distinct organspecific metastatic patterns were observed across subtypes: Basal-like tumors showed lung metastasis, HER2-enriched subtypes favored liver metastasis, and Luminal subtypes preferentially metastasized to bone. These metastatic patterns were supported by subtype-specific gene expression profiles, suggesting that key genes may drive both comorbidity and metastasis. DISCUSSION: The integration of gene expression and comorbidity profiling highlights the molecular mechanisms that link breast cancer progression with associated diseases. These findings provide valuable insights into how comorbid conditions may influence therapeutic responses and treatment planning. Subtype-specific metastasis further emphasizes the role of molecular drivers in determining clinical outcomes and offers an avenue for more tailored interventions.
conclusionThis study underscores the importance of comorbidity profiling in breast cancer. Our findings provide perspectives for developing personalized therapeutic strategies and may aid in improving clinical management and long-term outcomes for breast cancer patients.
Indexed as
Identifiers
41879447What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.